Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Mar 21 2022

Full Issue

AstraZeneca Treatment, Vaccines Said To Be Effective Against Omicron Subvariants

AstraZeneca released lab results that shows its antibody cocktail Evusheld effectively prevents and treats against the omicron subvariants. Separate research finds that vaccine protection also held up during the omicron surge and that people who were boosted fared better than those who weren't.

Reuters: AstraZeneca COVID Drug Neutralises Omicron Sub-Variants In Lab Study

AstraZeneca said on Monday its antibody-based cocktail to prevent and treat COVID-19 retained neutralising activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study. This is the first data looking at the impact of AstraZeneca's Evusheld treatment on "cousins" of the Omicron variant following a recent global spike in cases. The Anglo-Swedish drugmaker said in December that another lab study found that Evusheld retained neutralising activity against Omicron. (3/21)

In more news about covid treatments and vaccines —

The Washington Post: Vaccines Remained Highly Effective At Preventing Serious Illness And Death During Omicron Surge, CDC Report Says 

The coronavirus vaccines most widely used in the United States remained highly effective at preventing the worst outcomes from infections even in the face of the highly transmissible omicron variant in January, a report released Friday by federal disease trackers shows. While protection against mild illness waned over time, the mRNA vaccines from Moderna and Pfizer-BioNTech provided a robust shield against death and needing mechanical ventilation, the study from the Centers for Disease Control and Prevention found. (Shepherd, 3/18)

Stat: Covid-19 Vaccine Market Is Getting Crowded — As Demand Begins To Wane

CureVac, a pioneer in the effort to use messenger RNA as a vaccine platform, and its partner, pharmaceutical giant GSK, saw the writing on the wall last fall. When CureVac’s Covid-19 mRNA vaccine candidate underwhelmed in a Phase 2b/3 trial, the pair shifted plans. Too many other vaccines had already proven superior and been cleared by regulators. Rather than spend months tweaking a candidate that would end up battling for a rapidly shrinking share of the Covid vaccine market, they would focus instead on a second-generation product. Soon, experts tell STAT, other would-be Covid vaccine manufacturers are set to confront the same kinds of hard reality. (Branswell, 3/21)

CNN: Where The US Stands On Covid-19 Vaccines For Children Under 5 

A month after the US Food and Drug Administration delayed key steps toward authorizing Covid-19 vaccines for children under 5, many parents are more eager for the shots than ever. Dr. Daniel Leonard, a pediatric hospitalist who is working on the Pfizer/BioNTech vaccine trial for these kids, said people are driving in from several states away to take part. "We're here in south central Nebraska, and while many may not think that this would be the epicenter of scientific progress, the influx that I've had with people from Colorado, Minnesota, Wisconsin, Iowa -- some driving eight or nine hours each way overnight to participate in the study," he said. "They are dedicated." (Christensen, 3/19)

KHN: Pfizer CEO Pushes Yearly Shots For Covid. Not So Fast, Experts Say. 

When Pfizer CEO Albert Bourla said March 13 that all Americans would need a second booster shot, it struck many covid experts as a self-serving remark without scientific merit. It also set off spasms of doubt over the country’s objectives in its fight against the coronavirus. The decision on how often and widely to vaccinate against covid-19 is part science, part policy, and part politics. Ultimately it depends on the goals of vaccination at a time when it’s becoming clear that neither vaccines nor other measures can entirely stop the viral spread. (Allen, 3/21)

Also —

CBS News: "We Trust The COVID Vaccine," Heads Of Top Medical Groups Say In Ads Targeting Parents 

The heads of some of America's largest professional health care associations are urging parents to get their children vaccinated against COVID-19, as part of a new advertising push by the Biden administration to persuade millions of families that have yet to do so. The ads — a pair of 60-second spots titled "Oath" and "Trust" – feature pleas from Dr. Gerald Harmon, president of the American Medical Association; Dr. Moira Szilagyi, president of the American Academy of Pediatrics; Ernest Grant, president of the American Nurses Association; and Dr. Ada Stewart, chair of the board of the American Academy of Family Physicians. (Tin, 3/17)

NBC News: Is Tinnitus A Rare Side Effect Of Covid Vaccines?

It was the shock of a loud whistle that almost caused Gregory Poland to veer off the road as he was driving home after getting his second Covid-19 vaccine. "It startled me," said Poland, who is 66 years old. "I thought it was a dog whistle going off right next to me. "It was not a dog whistle; it was a piercing sound his brain conjured up for an unknown reason. Poland suspects it may have been a side effect of the vaccine. That was one year ago. The noise, he said, has been unrelenting ever since. (Edwards, 3/20)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 29
  • Thursday, May 28
  • Wednesday, May 27
  • Tuesday, May 26
  • Friday, May 22
  • Thursday, May 21
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF